Log in
NASDAQ:AVEO

AVEO Pharmaceuticals Stock Forecast, Price & News

$5.90
+0.15 (+2.61 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.65
Now: $5.90
$5.92
50-Day Range
$4.56
MA: $5.88
$6.68
52-Week Range
$2.23
Now: $5.90
$10.71
Volume141,859 shs
Average Volume297,265 shs
Market Capitalization$152.28 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical needs. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase III TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, acute myeloid leukemia, and pancreatic cancer; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. AVEO Pharmaceuticals, Inc. has collaboration and license agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Kirin Co., Ltd. AVEO Pharmaceuticals, Inc. has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Read More
AVEO Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AVEO
CUSIP05358810
Phone857-400-0101
Employees19

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$28.80 million
Cash Flow$0.61 per share
Book Value$0.92 per share

Profitability

Net Income$9.39 million

Miscellaneous

Market Cap$152.28 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$5.90
+0.15 (+2.61 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AVEO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions

How has AVEO Pharmaceuticals' stock been impacted by Coronavirus?

AVEO Pharmaceuticals' stock was trading at $3.49 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AVEO shares have increased by 69.1% and is now trading at $5.90.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of AVEO Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AVEO Pharmaceuticals
.

When is AVEO Pharmaceuticals' next earnings date?

AVEO Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for AVEO Pharmaceuticals
.

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) released its quarterly earnings data on Monday, August, 10th. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.09. The biopharmaceutical company earned $0.75 million during the quarter, compared to the consensus estimate of $1.48 million. AVEO Pharmaceuticals had a negative return on equity of 16.78% and a negative net margin of 13.28%.
View AVEO Pharmaceuticals' earnings history
.

When did AVEO Pharmaceuticals' stock split? How did AVEO Pharmaceuticals' stock split work?

AVEO Pharmaceuticals's stock reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 19th 2020. An investor that had 100 shares of AVEO Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for AVEO?

5 Wall Street analysts have issued 12-month price objectives for AVEO Pharmaceuticals' stock. Their forecasts range from $7.00 to $26.00. On average, they anticipate AVEO Pharmaceuticals' share price to reach $17.80 in the next year. This suggests a possible upside of 201.7% from the stock's current price.
View analysts' price targets for AVEO Pharmaceuticals
.

Who are some of AVEO Pharmaceuticals' key competitors?

What other stocks do shareholders of AVEO Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Opko Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA).

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the following people:
  • Mr. Michael P. Bailey, CEO, Pres & Director (Age 55, Pay $854.4k)
  • Ms. Karuna Rubin, Sr. VP & Gen. Counsel (Age 43, Pay $473.37k)
  • Dr. Michael N. Needle, Chief Medical Officer (Age 60, Pay $597.64k)
  • Mr. Erick J. Lucera CPA, CFA, Chief Financial Officer (Age 52)
  • Ms. Lisa M. Bruneau, VP of Financial Accounting & Reporting and Treasurer (Age 53)

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $5.90.

How big of a company is AVEO Pharmaceuticals?

AVEO Pharmaceuticals has a market capitalization of $152.28 million and generates $28.80 million in revenue each year. The biopharmaceutical company earns $9.39 million in net income (profit) each year or $0.61 on an earnings per share basis. AVEO Pharmaceuticals employs 19 workers across the globe.

What is AVEO Pharmaceuticals' official website?

The official website for AVEO Pharmaceuticals is www.aveooncology.com.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is 30 WINTER STREET, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 857-400-0101 or via email at [email protected]

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.